Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,001.61
    -70.02 (-1.38%)
     

  • Dow

    37,773.82
    -687.10 (-1.79%)
     

  • Nasdaq

    15,438.64
    -274.11 (-1.74%)
     

  • Bitcoin USD

    63,369.05
    -1,852.91 (-2.84%)
     

  • CMC Crypto 200

    1,374.35
    -8.22 (-0.59%)
     

  • FTSE 100

    8,062.69
    +22.31 (+0.28%)
     

  • Gold

    2,355.50
    +17.10 (+0.73%)
     

  • Crude Oil

    82.23
    -0.58 (-0.70%)
     

  • 10-Yr Bond

    4.7120
    +0.0600 (+1.29%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

How Moderna Went From Coronavirus Sequence to a Phase-1-Ready Vaccine Candidate in 42 Days

Brian Orelli, PhD, The Motley Fool
·2-min read
How Moderna Went From Coronavirus Sequence to a Phase-1-Ready Vaccine Candidate in 42 Days

Moderna (NASDAQ: MRNA), one of the leaders in the race to develop a coronavirus vaccine, was able to take the initial coronavirus sequence and get a vaccine candidate, mRNA-1273, ready for a phase 1 clinical trial in just 42 days. The biotech's use of Amazon Web Services (AWS), the cloud-based computing service run by Amazon (NASDAQ: AMZN), enabled this quick development. Moderna runs its Drug Design Studio on AWS, which allows it to design its mRNA drug candidates quickly.

Continue reading